Amryt Pharma (AMYT) Receives a Buy from H.C. Wainwright
November 04 2022 - 06:25AM
TipRanks
In a report released today, Douglas Tsao from H.C. Wainwright
reiterated a Buy rating on Amryt Pharma (AMYT - Research Report),
with a price target of $18.00. The company's shares closed
yesterday at $7.09.Tsao covers the Healthcare sector, focusing on
stocks such as Revance Therapeutics, Daré Bioscience, and Apellis
Pharmaceuticals. According to TipRanks, Tsao has an average return
of 1.6% and a 37.80% success rate on recommended stocks. Currently,
the analyst consensus on Amryt Pharma is a Moderate Buy with an
average price target of $18.50.See the top stocks recommended by
analysts >>The company has a one-year high of $12.17 and a
one-year low of $5.61.
https://www.tipranks.com/news/blurbs/amryt-pharma-amyt-receives-a-buy-from-h-c-wainwright?utm_source=advfn.com&utm_medium=referral
Amryt Pharma (NASDAQ:AMYT)
Historical Stock Chart
From Nov 2023 to Dec 2023
Amryt Pharma (NASDAQ:AMYT)
Historical Stock Chart
From Dec 2022 to Dec 2023